There is no single best treatment for invasive ductal carcinoma (IDC). The most effective approach depends on three factors: the tumor’s stage, its hormone receptor status, and whether it overproduces a protein called HER2. Treatment almost always involves surgery combined with some mix of radiation, chemotherapy, hormone-blocking drugs, or targeted therapies tailored to the tumor’s biology. Five-year survival rates reflect how much staging matters: 85.6% for localized disease, 79.6% for regional spread, and 46.6% when cancer has reached distant organs.
Why Tumor Subtype Drives Every Decision
Before any treatment plan takes shape, your tumor is tested for two things: hormone receptors (estrogen and progesterone) and HER2 status. These results sort IDC into four broad categories, and each one follows a different treatment path.
- HR-positive, HER2-negative is the most common subtype. It responds to hormone-blocking drugs and sometimes needs chemotherapy depending on genomic test results.
- HR-positive, HER2-positive (sometimes called triple-positive) is treated with chemotherapy, HER2-targeted drugs, and then long-term hormone therapy.
- HR-negative, HER2-positive relies on chemotherapy paired with HER2-targeted drugs.
- Triple-negative (no hormone receptors, no HER2) has the fewest targeted options and is treated primarily with chemotherapy, often combined with immunotherapy.
This subtyping isn’t optional or supplementary. It fundamentally determines which drugs will work, whether chemotherapy is necessary, and how long treatment lasts.
Surgery: Lumpectomy vs. Mastectomy
Most people with IDC will have surgery as a core part of treatment. The two main options are breast-conserving surgery (lumpectomy), which removes the tumor and a margin of surrounding tissue, and mastectomy, which removes the entire breast. For many patients, both options produce equivalent long-term results.
A large analysis of patients who had chemotherapy before surgery found that those in the lumpectomy group had a breast cancer-specific death rate of 2.18%, compared to 4.31% in the mastectomy group. Overall death rates were 3.13% versus 4.93%. That doesn’t mean lumpectomy is inherently superior. Patients selected for lumpectomy often have smaller, more favorable tumors. After adjusting for those differences, overall survival was statistically similar between the two groups.
A separate 10-year follow-up of nearly 1,000 patients found breast cancer-specific survival of 96.6% for lumpectomy versus 88.3% for mastectomy. These numbers are encouraging for patients who prefer to keep their breast, but the choice also depends on tumor size, location, genetic risk factors, and personal preference. Lumpectomy is almost always followed by radiation therapy.
Radiation After Surgery
If you have a lumpectomy, radiation to the remaining breast tissue is standard. It dramatically lowers the chance of cancer returning in the same breast. Two main schedules exist. Conventional radiation delivers treatment over 25 to 30 sessions across about five weeks. Hypofractionated radiation compresses the course into 10 to 15 sessions over two to three weeks, delivering a slightly larger dose per session.
Both approaches produce comparable outcomes for most patients, and hypofractionation has become increasingly common because it’s more convenient and less costly. Either way, you’ll typically go in five days a week until the course is complete. For some older patients with small, hormone-positive tumors and no lymph node involvement, the benefit of radiation after lumpectomy is modest. One study of women 70 and older with early-stage, estrogen receptor-positive tumors found no significant difference in 10-year survival whether or not they received radiation after surgery.
Chemotherapy: Before or After Surgery
Chemotherapy can be given before surgery (neoadjuvant) or after (adjuvant), and the timing depends on the clinical situation.
Neoadjuvant chemotherapy is commonly recommended for triple-negative tumors larger than 2 cm or those with positive lymph nodes, and for HER2-positive cancers where shrinking the tumor could make breast-conserving surgery possible. The goal is to reduce tumor size before the operation. It also provides a real-time test of how well the cancer responds to the drugs. If the tumor disappears completely on pathology after surgery, that’s called a pathologic complete response, which is linked to better long-term outcomes.
Adjuvant chemotherapy is given after surgery to eliminate any cancer cells that may have spread beyond the breast. Whether it’s needed for HR-positive, HER2-negative tumors often depends on genomic testing.
Genomic Testing for HR-Positive Tumors
If your tumor is hormone receptor-positive and HER2-negative, your oncologist will likely order a genomic test such as Oncotype DX. This test analyzes the activity of specific genes in the tumor and produces a recurrence score that helps predict how much benefit you’d get from adding chemotherapy to hormone therapy.
Patients are grouped into risk categories based on their score: low risk (under 18), medium risk (18 to 30), and high risk (above 30). The corresponding rates of distant recurrence are approximately 6.8%, 14.3%, and 30.5%. For patients with scores below 18, hormone therapy alone is typically sufficient. A score of 18 or above, particularly in women 45 or younger, is associated with improved disease-free survival when chemotherapy is added. This test has spared many patients from unnecessary chemotherapy while identifying those who genuinely benefit from it.
Hormone Therapy for HR-Positive Disease
If your cancer is hormone receptor-positive, you’ll take hormone-blocking medication for years after surgery and any chemotherapy. This is one of the most effective tools for preventing recurrence, and the minimum recommended duration is five years.
For postmenopausal women, aromatase inhibitors are generally preferred. These drugs block the body’s production of estrogen in tissues outside the ovaries. For premenopausal women, treatment may involve tamoxifen (which blocks estrogen from reaching cancer cells) or an aromatase inhibitor combined with ovarian function suppression. Premenopausal women with higher-risk disease tend to have better outcomes with the combination approach.
For patients with higher-stage disease, extending hormone therapy beyond five years offers additional protection. Two major trials showed that 10 years of tamoxifen versus five years reduced recurrence by 3% to 4% and breast cancer death by about 2.8%. Switching to an aromatase inhibitor after five years of tamoxifen reduced recurrences by an additional 4.6%. Current guidance suggests five to seven years of therapy is reasonable for lower-risk patients with no or limited lymph node involvement, while those with four or more positive lymph nodes may benefit from up to 10 years. The decision balances the modest survival gains against side effects like joint pain, hot flashes, and bone thinning.
HER2-Targeted Therapy
About 15% to 20% of breast cancers overproduce HER2, a protein that fuels aggressive growth. Drugs that target HER2 have transformed outcomes for this subtype.
The backbone of treatment is trastuzumab, a drug that attaches to the HER2 protein on cancer cells, blocking growth signals and flagging the cells for destruction by the immune system. For tumors larger than 2 cm, trastuzumab is typically paired with pertuzumab, which binds to a different part of the HER2 protein and prevents it from partnering with other receptors. Both are given alongside chemotherapy before surgery and continued afterward.
When cancer persists or returns despite first-line treatment, a newer class of drugs called antibody-drug conjugates delivers chemotherapy directly into HER2-positive cells. One of these, trastuzumab deruxtecan, carries a potent cell-killing agent attached to the trastuzumab molecule. It was approved by the FDA in late 2025 in combination with pertuzumab as a first-line option for metastatic HER2-positive breast cancer, representing a significant shift in how advanced disease is treated. An older antibody-drug conjugate, trastuzumab emtansine, remains an option for patients whose tumors don’t completely respond to initial therapy.
Immunotherapy for Triple-Negative IDC
Triple-negative breast cancer lacks the receptors that hormone therapy and HER2-targeted drugs exploit, which historically left chemotherapy as the only systemic option. Immunotherapy has changed that picture, though it works best in specific situations.
For early-stage triple-negative disease, the addition of pembrolizumab (an immune checkpoint inhibitor) to standard chemotherapy before surgery increased complete tumor disappearance rates from 51.2% to 64.8% in a major trial. The treatment protocol involves pembrolizumab alongside chemotherapy before surgery, followed by continued pembrolizumab after surgery for up to nine additional cycles.
In advanced triple-negative disease, immunotherapy benefits are concentrated in patients whose tumors test positive for a protein called PD-L1. Among those patients, adding pembrolizumab to chemotherapy extended median survival by nearly seven months (23 months versus 16.1 months). For PD-L1-negative patients, the benefit is minimal. As a single agent, immunotherapy works in only about 20% of patients with PD-L1-positive metastatic triple-negative disease, which is why it’s almost always combined with chemotherapy.
How Treatments Are Sequenced
Treatment for IDC isn’t a single event. It unfolds in phases over months or years. A typical sequence for a patient with a locally advanced, hormone-positive, HER2-negative tumor might look like this: genomic testing, then surgery, then radiation, then five to ten years of hormone therapy. A patient with triple-negative disease might start with several months of chemotherapy combined with immunotherapy, proceed to surgery, continue immunotherapy afterward, and then have radiation.
For HER2-positive tumors, treatment often begins with chemotherapy plus targeted drugs before surgery, continues targeted therapy after surgery for up to a year, and adds hormone therapy on top if the tumor is also hormone receptor-positive. The layering of treatments is what makes modern IDC management effective. Each element targets a different vulnerability, and skipping steps meaningfully increases the risk of recurrence.